Antipsychotic market
Executive Summary
Johnson & Johnson's Risperdal led the U.S. antipsychotic market with a 23.8% share of total prescriptions in June, according to IMS data provided to the company. Lilly's Zyprexa held a 17.5% share, followed by J&J's Haldol with a 14.5% share, Novartis' Clozaril with a 7.6% share and Zeneca's Seroquel with a 2.3% share. "The Pink Sheet" (Aug. 10, p. 18) incorrectly identified the market leader